aJohns Hopkins Ciccarone Center for Prevention of Cardiovascular Disease, Baltimore 21287, MD, USA bCenter for Heart Disease Prevention, Emory University School of Medicine, Atlanta, GA, USA ...
Zacks Investment Research on MSN
NVO rallies 11% in a month: How should investors play the stock?
Novo Nordisk NVO shares have rallied 11.2% over a month as investors regained confidence in the company's obesity growth ...
But at this stage of Eli Lilly's crucial obesity-drug business, the greenest pastures are currently overseas.
Collaboration will leverage the RaniPill® platform to explore oral delivery of PegBio's proprietary portfolio of novel obesity and metabolic disease molecules ~ ~ Agreement expands Rani's obesity fran ...
Large analysis finds no significant link between GLP-1 receptor agonist exposure and major birth defects, though urinary ...
Novo Nordisk updates Wegovy labeling in Singapore with STEP UP clinical data as S&P 500 healthcare developments continue ...
Zacks Investment Research on MSN
Buyout buzz around VKTX is back: What's fueling the speculation?
Although Viking Therapeutics VKTX isn’t officially on the auction block, investors are increasingly viewing it as a potential ...
All Active Patients in Both Cohorts Have Successfully Reached Highest Target Doses of 48 mg and 64 mg Topline Data Remains on Track for Fourth Quarter 2026 CAMBRIDGE ...
In late June 2026, Innovent Biologics announced a distribution and promotion agreement giving it sole commercialization ...
Fascinating nervous system imaging reveals previously unseen obesity-related nerve damage in mice and humans — and some of it ...
Viking Therapeutics recently initiated a Phase 1 single ascending dose trial of VK3019, a dual amylin and calcitonin receptor ...
Detailed price information for Novo Nordisk A/S ADR (NVO-N) from The Globe and Mail including charting and trades.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results